STRO - Sutro Biopharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Sutro Biopharma, Inc.

310 Utah Avenue
Suite 150
South San Francisco, CA 94080
United States
650 392 8412

Full Time Employees177

Key Executives

NameTitlePayExercisedYear Born
Mr. William J. NewellCEO & Director719.92kN/A1958
Dr. Trevor J. HallamChief Scientific Officer700.48kN/A1959
Dr. Arturo M. MolinaChief Medical Officer616.76kN/A1959
Dr. Shabbir T. AnikChief Technical Operations OfficerN/AN/A1953
Dr. James R. SwartzFounder and Member of Scientific Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Corporate Governance

Sutro Biopharma, Inc.’s ISS Governance QualityScore as of December 7, 2019 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.